The retrospective analysis- Percutaneous Hepatic Perfusion (Chemosaturation) with Melphalan in Patients with Intrahepatic Cholangiocarcinoma: European Multicentre Study on Safety, Short Term Effects and Survival
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2018
Price : $35 *
At a glance
- Drugs Melphalan (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Therapeutic Use
- 11 Oct 2018 New trial record
- 04 Oct 2018 According to a Delcath Systems media release, Dr. Steffen Marquardt of Hannover Medical School is the lead author of this study.
- 04 Oct 2018 Results presented in the Delcath Systems media release.